

GRIFOLS CORPORATE STATEMENT ON THE NOVEL CORONAVIRUS (SARS-CoV-2)

Updated April 23, 2020

Grifols has begun [identifying, screening and selecting volunteer donors](#) who have recovered from COVID-19 to donate their plasma at Grifols donor centers in select U.S. cities. The plasma will be used to produce an anti-SARS CoV-2 hyperimmune globulin that, if proven effective, could potentially treat the disease.

This initiative is a result of the [collaboration](#) between the company and the U.S. Government including the FDA, the Biomedical Advanced Research Development Authority (BARDA), which is part of the [Department of Health and Human Services](#) (HHS), and the U.S. Department of Defense's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (DoD-JPEO-CBRND).

In Spain, Grifols has already begun viral inactivation of convalescent plasma (methylene blue) that will be used for transfusion as part of a 100-patient clinical trial it's leading and for which recovered COVID-19 patients are donating their plasma. The trial currently features six hospitals: in Barcelona, Bellvitge and Vall d'Hebron; in Madrid, Clínico San Carlos, La Paz and Fundación Jiménez Díaz; and in Santiago de Compostela, Clínico Universitario de Santiago.

Grifols will soon lead two more clinical trials in Spain with existing plasma-derived therapies: one with high-dose immunoglobulin infusions in 100 COVID-19 patients from six hospitals, another one with alpha-1 antitrypsin also in 100 COVID-19 patients from four hospitals.

At the same time, Grifols has developed a highly sensitive automated test to detect SARS-CoV-2 based on TMA (Transcription Mediated Amplification) technology, which will soon be available.

Grifols will regularly update materials and statements on our fight against COVID-19 [here](#).

GRIFOLS